Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.

Vaccine. 2006 Aug 14;24(33-34):5950-9.

PMID:
16797805
2.

Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.

Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL.

Hum Vaccin. 2007 Sep-Oct;3(5):205-11.

PMID:
17881903
3.

Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.

Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr.

Vaccine. 2006 Apr 24;24(17):3654-60.

PMID:
16497418
4.

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM.

Vaccine. 2002 Jan 31;20(9-10):1412-20.

PMID:
11818160
6.

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.

Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.

Vaccine. 2006 Jul 7;24(27-28):5627-36.

PMID:
16740348
8.

Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R.

Clin Vaccine Immunol. 2012 Feb;19(2):140-5. doi: 10.1128/CVI.05556-11.

9.

Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.

Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, DeMuria D, Ransom J, Quinn J, Nabors GS, Nielsen CJ.

Vaccine. 2011 Aug 26;29(37):6313-20. doi: 10.1016/j.vaccine.2011.05.047.

PMID:
21624418
11.

Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.

Parreiras PM, Sirota LA, Wagner LD, Menzies SL, Arciniega JL.

Vaccine. 2009 Jul 16;27(33):4537-42. doi: 10.1016/j.vaccine.2009.05.045.

PMID:
19501205
13.

Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.

Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT Jr, Friedlander AM, Sjogren MH.

Vaccine. 2002 May 15;20(16):2107-15.

PMID:
11972980
14.

Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.

Little SF, Ivins BE, Webster WM, Norris SL, Andrews GP.

Vaccine. 2007 Apr 12;25(15):2771-7.

PMID:
17240008
15.

Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML.

PLoS One. 2010 Nov 5;5(11):e13849. doi: 10.1371/journal.pone.0013849.

16.

A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, Rudge TL, Mayfield HJ, Schiffer J, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Brys AM, Hunt RE, Levesque D, Estep JE, Barnewall RE, Robinson DM, Plikaytis BD, Marano N; AVRP Laboratory Working Group..

Clin Vaccine Immunol. 2012 Nov;19(11):1730-45. doi: 10.1128/CVI.00324-12.

17.

Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.

Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.

Bull Pan Am Health Organ. 1995 Dec;29(4):312-21.

PMID:
8605522
18.

Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.

Krishnan V, Andersen BH, Shoemaker C, Sivko GS, Tordoff KP, Stark GV, Zhang J, Feng T, Duchars M, Roberts MS.

Clin Vaccine Immunol. 2015 Apr;22(4):430-9. doi: 10.1128/CVI.00690-14.

19.

Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.

Pittman PR, Fisher D, Quinn X, Schmader T, Barrera-Oro JG.

Vaccine. 2013 Oct 17;31(44):5009-14. doi: 10.1016/j.vaccine.2013.08.086.

PMID:
24026013
20.

Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.

Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP.

Vaccine. 2014 Feb 12;32(8):1019-28. doi: 10.1016/j.vaccine.2013.10.039.

PMID:
24373307
Items per page

Supplemental Content

Support Center